Annals of Thoracic Medicine
COMMENTARY
Year
: 2022  |  Volume : 17  |  Issue : 4  |  Page : 185--188

When single-inhaler triple therapy is a preferred option in asthma management?


Mohamed S Al-Moamary1, Riyad Al-Lehebi2, Majdy M Idrees3, Mohammed O Zeitouni4 
1 Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
2 Pulmonary Section, Department of Medicine, King Fahad Medical City; Department of Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
3 Department of Medicine, Respiratory Division, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
4 Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Correspondence Address:
Prof. Mohamed S Al-Moamary
Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh
Saudi Arabia

Asthma control is the main goal of management. Unfortunately, most asthma patients with moderate–severe asthma remain uncontrolled despite receiving standard treatment of inhaled corticosteroids (ICS) with long-acting β2 agonists (LABA). The addition of long-acting antimuscarinic agents (LAMA) has been shown to improve different aspects of asthma control, including symptoms, lung functions, and probably exacerbations. Such an option could be considered for low-T2 asthma phenotype. Umeclidinium and glycopyrronium bromide are other LAMA agents that have been recently made available in combination with ICS and LABA in single-inhaler triple therapy (SITT) devices. Here, we discuss the position of SITT as a new novel therapeutic option in asthma management and its clinical benefits, potential cost saving, and improved compliance.


How to cite this article:
Al-Moamary MS, Al-Lehebi R, Idrees MM, Zeitouni MO. When single-inhaler triple therapy is a preferred option in asthma management?.Ann Thorac Med 2022;17:185-188


How to cite this URL:
Al-Moamary MS, Al-Lehebi R, Idrees MM, Zeitouni MO. When single-inhaler triple therapy is a preferred option in asthma management?. Ann Thorac Med [serial online] 2022 [cited 2023 Feb 2 ];17:185-188
Available from: https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2022;volume=17;issue=4;spage=185;epage=188;aulast=Al-Moamary;type=0